Senior Director, Cardiovascular and Cardiometabolic Translational Biology

We create a place where people can grow, be their best, be safe, and feel welcome, valued and included. We offer a competitive salary, an annual bonus based on company performance, healthcare and wellbeing programmes, pension plan membership, and shares and savings programme.

We embrace modern work practises; our Performance with Choice programme offers a hybrid working model, empowering you to find the optimal balance between remote and in-office work.

Discover more about our company wide benefits and life at GSK on our webpage Life at GSK | GSK

Senior Director, Cardiovascular and Cardiometabolic Translational Biology

The Respiratory, Immunology, and Inflammation Research Unit (RIIRU) uses immune science to address underlying organ dysfunction and disease, building a pipeline of medicines to transform treatment and care. Our diverse team of industry-leading experts turns scientific exploration into value for patients and GSK. We span the full R&D journey, from early discovery and mid-stage development to launching late-stage medicines. By combining leading datasets, capabilities and methods with decades of scientific expertise, we are reshaping how we develop and deliver new medicines.

GSK is expanding cardiovascular and cardiometabolic capabilities within RIIRU, initially focusing on cardiovascular disease as a key co-morbidity across respiratory, renal, hepatology and neurodegeneration. The next step is to sharpen the strategy, deepen internal expertise and build a portfolio that complements existing disease-area programmes.

This is an opportunity to build, rather than inherit, a scientific direction. As the senior Translational Biology expert in cardiovascular science, you will evaluate existing targets, develop a human-first strategy, identify collaboration and business development opportunities, and guide investment priorities. You will provide key scientific recommendations within a matrix, partnering with clinical, genetics, genomics, disease-area and portfolio leaders.

You will shape the strategy, scientific network and future portfolio, with immediate visibility across four established disease areas where cardiovascular biology can improve patient outcomes. Early involvement in emerging collaborations - including relationships with academic institutions and potential international partners - will allow you to bring together internal target science, external innovation and business development to build a differentiated portfolio.

The remit spans cardiovascular, vascular and cardiometabolic biology rather than a narrow single-disease specialism, offering senior influence without direct authority and the freedom to convene experts and turn evidence into portfolio recommendations.

For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029.

In this role you will

Scientific and Translational Leadership (Individual Contributor):

• Provide scientific leadership to progress an existing preclinical and clinical cardiovascular portfolio by defining clear, human-relevant mechanistic hypotheses
• Provide scientific leadership to progress an existing preclinical and clinical cardiovascular portfolio by defining clear, human-relevant mechanistic hypotheses
• Drive programs focused on cardiovascular disease biology, including vascular inflammation, endothelial dysfunction, fibrosis, remodeling, thrombosis, pulmonary vascular disease, heart failure-related mechanisms, and cardio-renal-metabolic disease pathways. Deliver translational strategies that incorporate human genetics, multi-omics, and reverse translation to strengthen target confidence and clinical relevance.
• Drive programs focused on cardiovascular disease biology, including vascular inflammation, endothelial dysfunction, fibrosis, remodeling, thrombosis, pulmonary vascular disease, heart failure-related mechanisms, and cardio-renal-metabolic disease pathways. Deliver translational strategies that incorporate human genetics, multi-omics, and reverse translation to strengthen target confidence and clinical relevance.
• Provide leadership on biomarker strategies, including target engagement, pharmacodynamic, disease activity, risk stratification, and patient-selection biomarkers that enable confident translation from preclinical models to clinical studies. Monitor scientific and competitive landscapes to identify emerging opportunities and potential portfolio risks and recommend evidence-based actions.

…